BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32401432)

  • 1. Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.
    Reim D; Novotny A; Friess H; Slotta-Huspenina J; Weichert W; Ott K; Dislich B; Lorenzen S; Becker K; Langer R
    J Pathol Clin Res; 2020 Oct; 6(4):263-272. PubMed ID: 32401432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Impact of the Location of Lymph Node Metastases After Neoadjuvant Chemotherapy for Middle and Lower Thoracic Esophageal Cancer.
    Miyata H; Sugimura K; Yamasaki M; Makino T; Tanaka K; Morii E; Omori T; Yamamoto K; Yanagimoto Y; Yano M; Nakatsuka S; Mori M; Doki Y
    Ann Surg Oncol; 2019 Jan; 26(1):200-208. PubMed ID: 30374924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
    Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
    World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
    Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of the location of metastatic lymph nodes in patients with adenocarcinoma of the oesophagogastric junction.
    Liu JF; Jiang T; Shi ZH; Liu XB
    ANZ J Surg; 2018 Mar; 88(3):218-222. PubMed ID: 27444989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
    Smyth EC; Fassan M; Cunningham D; Allum WH; Okines AF; Lampis A; Hahne JC; Rugge M; Peckitt C; Nankivell M; Langley R; Ghidini M; Braconi C; Wotherspoon A; Grabsch HI; Valeri N
    J Clin Oncol; 2016 Aug; 34(23):2721-7. PubMed ID: 27298411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
    Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
    Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
    Chau I; Norman AR; Cunningham D; Oates J; Hawkins R; Iveson T; Nicolson M; Harper P; Seymour M; Hickish T
    Ann Oncol; 2009 May; 20(5):885-91. PubMed ID: 19164454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection.
    Schmidt T; Alldinger I; Blank S; Klose J; Springfeld C; Dreikhausen L; Weichert W; Grenacher L; Bruckner T; Lordick F; Ulrich A; Büchler MW; Ott K
    Eur J Surg Oncol; 2015 Oct; 41(10):1340-7. PubMed ID: 26213358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer.
    Namura M; Tsunoda H; Kobayashi D; Enokido K; Yoshida A; Watanabe T; Suzuki K; Nakamura S; Yamauchi H; Hayashi N
    Clin Breast Cancer; 2019 Aug; 19(4):278-285. PubMed ID: 30975473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
    Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
    Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
    Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.
    Lagarde SM; Navidi M; Gisbertz SS; van Laarhoven HW; Sumpter K; Meijer SL; Disep B; Immanuel A; Griffin SM; van Berge Henegouwen MI
    Br J Surg; 2016 Nov; 103(12):1658-1664. PubMed ID: 27696382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
    Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
    Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.